Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
Completed
- Conditions
- Metastatic Renal Cell Cancer
- Registration Number
- NCT01926990
- Lead Sponsor
- Stanford University
- Brief Summary
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
- Suspected or biopsy-proven renal cell carcinoma
- Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib, nivolumab alone or in combination with an investigational agent
- Ability to understand and willingness to sign a written informed consent document
Read More
Exclusion Criteria
- Serum creatinine greater than or equal to 1.7 mg/dL
- Severe allergy to contrast agent
- Any contraindication for undergoing a CT scan
- Pregnancy or unwillingness to use preventative measures if a woman of child-bearing potential
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Characterization of the relationship between Change in blood flow measured through perfusion CT techniques and Change in tumor size measured through non-investigational CT 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication
- Secondary Outcome Measures
Name Time Method Characterization of the relationship between change in perfusion CT measurements (eg. Mean transit time) and change in tumor size measured by non-investigational CT 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication Relationship between change in blood flow and tumor response measured on ordinal scale 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication Relationship between change in blood flow at Day 8 and change in tumor size measured on continuous scale at Week 12 and tumor response measured on ordinal scale at Week 12 12 weeks (+/- 5 days) after start of standard systemic targeted therapy medication Relationship between change in blood flow at Day 8 and at Week 12 and progression-free survival 12 weeks after start of standard systemic targeted therapy medication Relationship between change in blood flow at Day 8 and at Week 12 and time to nadir of tumor size 12 weeks after start of standard systemic targeted therapy medication
Trial Locations
- Locations (1)
Stanford University Cancer Institute
🇺🇸Stanford, California, United States